The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice.
Kenneth C Gorson; Ivo N van Schaik; Ingemar S J Merkies; Richard A Lewis; Richard J Barohn; Carol L Koski; David R Cornblath; Richard A C Hughes; Angelika F Hahn; Mona Baumgarten; et al. (Profiled Author: Mona E Baumgarten)
Department of Neurology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA. firstname.lastname@example.org
Journal of the peripheral nervous system : JPNS 2010;15(4):326-33.
Defining long-term outcomes in chronic inflammatory demyelinating polyneuropathy (CIDP) has been complicated by varying definitions of treatment response and differing scales measuring impairment or disability. An expert panel was convened to devise a CIDP Disease Activity Status (CDAS) and to classify long-term outcome by applying it to 106 patients with a consensus diagnosis of CIDP. Sixty of these cases were graded blindly by three independent reviewers to assess inter-rater reliability. The mean duration of follow-up was 6.4 years (range, 3 months-23 years). Eleven percent of patients were classified as cured (stable examination and off treatment for ≥5 years), 20% were in remission (stable and off treatment for <5 years), 44% had stable active disease but required ongoing therapy for at least 1 year, 7% were improving after recent initiation of therapy, and 18% had unstable active disease (treatment naïve or treatment refractory). Excellent inter-rater reliability was observed (kappa scores: 0.93-0.97; p < 0.0001). The CDAS is considered a simple and reproducible tool to classify patients with CIDP according to disease activity and treatment status that can be applied easily in practice and potentially to select patients for clinical trials.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
J L Good; M Chehrenama; R F Mayer; C L KoskiNeurology 1998;51(6):1735-8.
Eleni Sarlani; Edward G Grace; Birute A Balciunas; Anthony H SchwartzJournal of the American Dental Association (1939) 2005;136(4):469-76.
C L Koski; M Baumgarten; L S Magder; R J Barohn; J Goldstein; M Graves; K Gorson; A F Hahn; R A C Hughes; J Katz; et al.Journal of the neurological sciences 2009;277(1-2):1-8.
Appears in this Publication
Author of this Publication